Our cohort of combined DBS‐LCIG therapy revealed improvement across most domains of PDQ‐39 with trend toward significance in activities of daily living, mobility, social, and body discomfort (Fig. 1 , Table 4 ). 17 , 18 LCIG can be entertained as a potential therapeutic option for the management of refractory fluctuations in PD patients following DBS.
← all excerpts
Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
1
—
—